To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100 - Trial NCT05684718
Access comprehensive clinical trial information for NCT05684718 through Pure Global AI's free database. This Phase 1 trial is sponsored by BioVersys AG and is currently Not yet recruiting. The study focuses on Bacterial Infections. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
BioVersys AG
Timeline & Enrollment
Phase 1
Feb 01, 2023
Dec 01, 2023
Primary Outcome
To evaluate the effect of repeated doses of itraconazole on the pharmacokinetics of intravenous rifabutin,To evaluate the effect of repeated doses of itraconazole on the pharmacokinetics of intravenous rifabutin,To evaluate the effect of repeated doses of itraconazole on the pharmacokinetics of intravenous 25-O-deacetyl-rifabutin,To evaluate the effect of repeated doses of itraconazole on the pharmacokinetics of intravenous 25-O-deacetyl-rifabutin
Summary
Phase I clinical study to evaluate the effect of multiple doses of itraconazole on the
 pharmacokinetics of BV100 in healthy volunteers.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05684718
Non-Device Trial